SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Amendment #6
Under the Securities Exchange Act of 1934
IMMULOGIC PHARMACEUTICAL CORPORATION
------------------------------------
(Name of Issuer)
Common Stock par value $.01 per share
- ---------------------------------------------------------------------------
(Title of Class of Securities)
45252R 10 0
-----------------
(CUSIP Number)
William K. Hoskins, Esq. Harry R. Benz
General Counsel Hoechst Corporation
Hoechst Marion Roussel, Inc. Route 202-206
9300 Ward Parkway P.O. Box 2500
Kansas City, Missouri 64114 Somerville, NJ 08876-1258
(816) 966-4000 (517) 636-1000
- ---------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
March 22, 1996
-------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(4)(i)(A) or (B), check the
following box. [ ]
Check the following box if a fee is being paid with this statement [ ].
Page 1 of 6
There is no Exhibit Index
<PAGE> 2
CUSIP No. 45252R 10 0
___________________________________________________________________________
1) Name of Reporting Person and its Hoechst Marion Roussel, Inc.
I.R.S. Identification Number 44-0565557
___________________________________________________________________________
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ x]
___________________________________________________________________________
3) SEC Use Only
___________________________________________________________________________
4) Source of Funds WC
___________________________________________________________________________
5) Check Box if Disclosure of Legal [ ]
Proceedings is Required Pursuant
to Items 2(d) or 2(e)
___________________________________________________________________________
6) Citizenship or Place of Organization Delaware
___________________________________________________________________________
7) Sole Voting Power 250,000*
Number of ____________________________________________________________
Shares
Beneficially 8) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 9) Sole Dispositive Power 250,000*
Person With ____________________________________________________________
10) Shared Dispositive Power 0
___________________________________________________________________________
11) Aggregate Amount Beneficially Owned 250,000*
by Each Reporting Person
___________________________________________________________________________
12) Check Box If the Aggregate Amount [ ]
in Row (11) Excludes Certain Shares
___________________________________________________________________________
13) Percent of Class Represented 1.26%
by Amount in Row (11)
___________________________________________________________________________
14) Type of Reporting Person CO
___________________________________________________________________________
* Represents only 250,000 shares that may be acquired on or before December
17, 1996, upon exercise of a stock option.
<PAGE> 3
CUSIP No. 45252R 10 0
___________________________________________________________________________
1) Name of Reporting Person and its Hoechst Corporation
I.R.S. Identification Number 22-1862783
___________________________________________________________________________
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ X ]
___________________________________________________________________________
3) SEC Use Only
___________________________________________________________________________
4) Source of Funds Not Applicable
___________________________________________________________________________
5) Check Box if Disclosure of Legal [ ]
Proceedings is Required Pursuant
to Items 2(d) or 2(e)
___________________________________________________________________________
6) Citizenship or Place of Organization Delaware
___________________________________________________________________________
7) Sole Voting Power 250,000*#
Number of ____________________________________________________________
Shares
Beneficially 8) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 9) Sole Dispositive Power 250,000*#
Person With ____________________________________________________________
10) Shared Dispositive Power 0
___________________________________________________________________________
11) Aggregate Amount Beneficially Owned 250,000*#
by Each Reporting Person
___________________________________________________________________________
12) Check Box If the Aggregate Amount [ ]
in Row (11) Excludes Certain Shares
___________________________________________________________________________
13) Percent of Class Represented 1.26%
by Amount in Row (11)
___________________________________________________________________________
14) Type of Reporting Person CO
___________________________________________________________________________
* Represents only 250,000 shares that may be acquired on or before December
17, 1996, upon exercise of a stock option.
# Hoechst Corporation disclaims beneficial ownership of these securities
(See Item 2 (a) - (c), (f)).
<PAGE> 4
This Amendment to the Statement on Schedule 13D (the "Schedule 13D")
with respect to the Common Stock of ImmuLogic Pharmaceutical Corporation
(the "Issuer"), of Hoechst Marion Roussel, Inc., a Delaware corporation
("HMRI", formerly Marion Merrell Dow Inc. ("MMD")), and Hoechst
Corporation, a Delaware corporation ("Parent"), is filed solely to report
the termination of the Schedule 13D filing obligation of HMRI and Parent
with respect to beneficial ownership of securities of the Issuer.
Item 5 of this Statement on Schedule 13D is hereby amended to read in
its entirety as follows:
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
- ------- ------------------------------------
In sales conducted between March 13 and March 22, 1996, HMRI sold all
1,000,000 shares of Common Stock of the Issuer owned by it in open market
and block transactions at prices ranging between $10.25 and $12.00 per
share. HMRI and Parent ceased to be the actual or deemed beneficial owners
of more than five percent of the Issuer's Common Stock on March 22, 1996.
The sole actual or deemed beneficial interest of HMRI or Parent in
securities of the Issuer is an option to purchase up to 250,000 shares of
the Issuer's Common Stock, which expires December 17, 1996.
<PAGE> 5
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
HOECHST MARION ROUSSEL, INC.
Date: March 22, 1996 By: /s/ William K. Hoskins
William K. Hoskins
Vice President,
General Counsel, and
Corporate Secretary
<PAGE> 6
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
HOECHST CORPORATION
Date: March 22, 1996 By: /s/ Alban W. Schuele
Alban W. Schuele
Vice President
